Meeting requested to address questions, inform planning for use of remdesivir, the only FDA-authorized drug for COVID-19 treatment.
H.R.6800, the Health Heroes Act, includes policies and investments that would bolster the federal response to COVID-19, increase testing capacity and availability of medical supplies and address the disparate impact of COVID-19 on vulnerable populations.
The U.S. Department of Health and Human Services decision allowing state health departments to distribute limited supplies of remdesivir to treat COVID-19 where they are needed will support fair and equitable access to the drug.
Strong and specific federal guidance is critical to protecting our country, our communities, our health and our lives in the face of the still escalating impacts of COVID-19 across the United States.
With FDA emergency authorization of remdesivir to treat COVID-19, the Infectious Diseases Society of America and its HIV Medicine Association are calling on Vice President Mike Pence and other administration officials to provide public transparency in the process for determining how and where the medication is distributed
Sepsis, a complication of infection that can cause low blood pressure (shock) as well as lung, kidney, and organ failure, affects an estimated 1.7 million adults each year in the U.S. and contributes to 270,000 deaths.
The Infectious Diseases Society of America has released 15 recommendations to assist clinicians, laboratory personnel and policy makers in decisions on the use of SARS-CoV-2 diagnostic testing for people with and without symptoms of COVID-19.
With data showing alarmingly high rates of COVID-19 infection among people who are incarcerated, the Infectious Diseases Society of America and its HIV Medicine Association today released policy recommendations to prevent and respond to the spread of the coronavirus in detention settings.
As leading public health and medical organizations, we represent front-line workers and experts who are witnessing the critical importance of maintaining physical distancing measures until data and resources indicate that lifting them is safe.
The Infectious Diseases Society of America has released eight recommendations on the use of personal protective equipment (PPE) for infection prevention among health care personnel caring for patients with suspected or confirmed COVID-19.
IDSA has developed a COVID-19 antibody testing primer for policymakers, scientists, and clinicians to drive research and appropriate use of serologic testing. At this time, more evidence is needed before implementing and expanding these tests for clinical and public health use.
IDSA and HIVMA warned today that prematurely easing social distancing measures put in place to curtail the spread of COVID-19 will risk increased infections and deaths, incapacitated health care facilities, and prolonged economic hardships.